New study shows higher lung cancer incidence in women than in men

NewsGuard 100/100 Score

Reversing historical patterns, new findings led by researchers at the American Cancer Society (ACS) show higher lung cancer incidence in women than in men has not only continued in adults younger than 50 years, but now extends to women 50 to 54 years of age in the United States. The findings are published today in the Journal of the American Medical Association (JAMA) Oncology.

These findings are very concerning. We don't know why lung cancer incidence rates among younger and middle-aged individuals are now higher in women than men, reversing the historical pattern. Cigarette smoking prevalence, the major risk factor for lung cancer in the United States, is not higher in younger women than younger men, as are other established risk factors such as occupational exposures."

Dr. Ahmedin Jemal, senior vice president, surveillance and health equity science at the American Cancer Society and lead author of the paper

For this cross-sectional study, researchers analyzed population-based incidence data on lung and bronchus cancers diagnosed from 2000 to 2019 from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program, covering nearly 50% of the U.S. population. Cases were categorized by sex and age in 5-year increments and year of diagnosis.

The study results showed the declines in lung cancer incidence rates between 2000-2004 and 2015-2019 were greater in men than women, leading to higher incidence in women aged 35-54 years. Among individuals aged 50-54 years, for example, the rate per 100,000 person-years decreased by 44% in men compared to 20% in women. As a result, the female-to-male incidence rate ratio increased from 0.73 during 2000-2004 to 1.05 during 2015-2019. Among individuals aged 55 years or older, however, incidence rates continued to be lower in women, although differences became increasingly smaller. Among persons aged 70 to 74 years, for example, the female-to-male incidence rate ratio increased from 0.62 during 2000-2004 to 0.81 during 2015-2019.

"Lung cancer is still the leading cause of cancer death in the U.S. with 80% of cases and deaths caused by cigarette smoking," said Jemal. "To mitigate the high burden of the disease in young and middle-aged women, greater effort is needed to promote tobacco cessation at provider and community levels, improve access to tobacco cessation aids and programs through expansion of Medicaid, and increase lung cancer screening in eligible women. Also, further research is needed to shed light on the reasons for the higher lung cancer incidence in younger and middle-aged women."

The American Cancer Society's advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN), continues to work at all levels of government to advocate for access to lung cancer screenings.

This research further amplifies the critical need for reducing all barriers to access to care to ensure that women are able to immediately address any symptoms as well as access preventive and early detection screenings at no cost. By removing barriers to screenings and adequately funding federal and state tobacco control programs, lawmakers can decrease lung cancer deaths and help end cancer as we know it, for everyone."

Lisa Lacasse, President of ACS CAN

Other ACS authors on the paper include: Elizabeth J. Schafer, Dr. Hyuna Sung, Dr. Priti Bandi, Tyler Kratzer, Dr. Farhad Islami, and Rebecca Siegel.

Source:
Journal reference:

Jemal, A., et al. (2023). The Burden of Lung Cancer in Women Compared With Men in the US. JAMA Oncology. doi.org/10.1001/jamaoncol.2023.4415.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First FDA-approved cellular therapy for metastatic melanoma available in South Florida